Literature DB >> 28221174

IgA nephropathy: an update.

Maria F Soares1, Ian S D Roberts.   

Abstract

PURPOSE OF REVIEW: To provide an update on recent developments since the publication of the Oxford Classification of IgA nephropathy and to consider lesions that were not included in the original classification. RECENT
FINDINGS: Over 20 validation studies of the Oxford Classification have been published. Tubular atrophy/interstitial fibrosis is consistently the strongest predictor of renal survival, whereas mesangial hypercellularity predicts rate of loss of renal function. Endocapillary hypercellularity and crescents are associated with lower renal survival and more rapid loss of renal function in patients not receiving immunosuppression, whereas crescents in at least 25% of glomeruli predict lower renal survival irrespective of treatment; a C score has been added to the MEST scores in the 2016 revision of the classification. Repeat biopsy studies have demonstrated response of endocapillary and extracapillary hypercellularity to immunosuppression. Podocytopathic changes in segmental sclerosis are associated with higher levels of proteinuria, renal function decline and worse renal survival. Combination of histological and clinical variables allow for earlier outcome prediction.
SUMMARY: Recent evidence supports the use of the Oxford Classification of IgA nephropathy in wider populations. Combination of histological, clinical and biomarker data promises more accurate prognostication and identification of patients who will benefit from immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28221174     DOI: 10.1097/MNH.0000000000000312

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  6 in total

1.  Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome.

Authors:  Xin Han; Yi Xiao; Yi Tang; Xiaonan Zheng; Mawluda Anwar; Wei Qin
Journal:  Clin Exp Med       Date:  2019-09-21       Impact factor: 3.984

2.  The Influence of ACE Insertion/Deletion Gene Polymorphism on the Risk of IgA Nephropathy: A Debatable Topic.

Authors:  Fen-Fen Chu; Shi-Kun Yang; Wen-Li Zeng
Journal:  Genet Res (Camb)       Date:  2021-11-18       Impact factor: 1.588

Review 3.  IgA Nephropathy: A European Perspective in the Corticosteroid Treatment.

Authors:  Rosanna Coppo
Journal:  Kidney Dis (Basel)       Date:  2018-03-16

4.  Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.

Authors:  Chen Tang; Ji-Cheng Lv; Su-Fang Shi; Yu-Qing Chen; Li-Jun Liu; Hong Zhang
Journal:  BMC Nephrol       Date:  2020-11-10       Impact factor: 2.388

5.  Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy.

Authors:  Precil Diego Miranda de Menezes Neves; Rafael A Souza; Fábio M Torres; Fábio A Reis; Rafaela B Pinheiro; Cristiane B Dias; Luis Yu; Viktoria Woronik; Luzia S Furukawa; Lívia B Cavalcante; Stanley de Almeida Araújo; David Campos Wanderley; Denise M Malheiros; Lectícia B Jorge
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

Review 6.  Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.

Authors:  Haresh Selvaskandan; Sufang Shi; Sara Twaij; Chee Kay Cheung; Jonathan Barratt
Journal:  Front Immunol       Date:  2020-10-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.